IL1RAP expression is highly correlated with the BCR-ABL1 translocation in CML LSCs, can be used as a measure of LSC burden and predictor of therapy outcome, and can be targeted by therapeutic mAbs to eradicate LSCs (285–287). Here, IL1RAP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.